“…To date, a large number of Eg5 inhibitors, such as STLC and PVZB1194, have been reported (Ogo et al, 2007;Matsuno et al, 2009). A large amount of structural information on Eg5 in complex with its inhibitors has also been reported (Yokoyama et al, 2015(Yokoyama et al, , 2018Myers & Collins, 2016). However, Eg5 inhibitors have not found clinical use because they target not only cancer cells but also other actively proliferating cells.…”